ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (NYSE Amex: RGN), a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, today announced that the underwriters of its recently completed public offering of units have exercised an option to purchase an additional 1,624,750 units at $0.41 per unit, consisting of an aggregate of 1,624,750 shares of common stock and warrants to purchase an aggregate of 649,900 shares of common stock. Each warrant has a term of five years and represents the right to purchase one share of common stock at an exercise price of $0.56 per share. No fractional warrants will be issued. The additional units separated immediately, and the common stock and warrants were issued separately. The warrants are quoted on the NASD Over the Counter Bulletin Board. The sale of the additional units occurred on June 2, 2010.
